Journal of Clinical Endocrinology & Metabolism, Vol 75, 30-36, Copyright © 1992 by Endocrine Society

ARTICLES

Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans

SA Lieberman, J Bukar, SA Chen, AC Celniker, PG Compton, J Cook, J Albu, AJ Perlman and AR Hoffman
Medical Service, Palo Alto Veterans Affairs Medical Center, California 94304.

To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days. Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP. Total IGF-I was measured by RIA after acid/ethanol extraction. Free IGF-I was separated from binding protein-complexed IGF-I using size exclusion high performance liquid chromatography before measurement by RIA. IGFBP were quantitated by optical densitometry of Western ligand blots. Total IGF-I increased significantly from 0-24 h after administration on day 1 (mean +/- SD, micrograms/L: 120 +/- 44 to 166 +/- 51, P = 0.0002) but did not increase significantly from 24 h on day 1 to 0 h on day 5 (166 +/- 51 to 178 +/- 62) or from 0-24 h on day 5 (178 +/- 62 to 209 +/- 89). The area under the total IGF-I concentration curve was greater on day 5 than day 1 (311 +/- 99 min.g/L vs. 249 +/- 77, P = 0.0001). There were no significant differences in free IGF-I concentration or pharmacokinetic parameters or in the degree or timing of hypoglycemia between days 1 and 5. Plasma insulin levels decreased significantly following rhIGF-I administration (day 1 baseline: 53 +/- 11 pmol/L, nadir: 18 +/- 6 pmol/L at 30 min, P = 0.003); day 5 baseline: 47 +/- 15 pmol/L, nadir: 16 +/- 8 pmol/L at 30 min, P = 0.0003. Western ligand blotting revealed the transient appearance of a 30-kilodalton band which migrates in a manner similar to IGFBP-1. This band was undetectable at baseline, peaked between 150 and 210 min after rhIGF-I administration, and diminished by 480-600 min. The response was similar on days 1 and 5. There were no substantial changes in the serum levels of any other IGFBP. In summary, repeated iv bolus administration of rhIGF-I increased the level of total circulating IGF-I without changing free IGF-I disposition or glycemic response. A 30-kilodalton IGFBP band, most likely IGFBP-1, appeared transiently following rhIGF-I administration, probably as a result of suppression of insulin levels. IGFBP-2, -3, and -4 were unaffected.

This article has been cited by other articles:

				A. Cittadini, J. D. Grossman, H. Stromer, S. E. Katz, J. P. Morgan, and P. S. Douglas Importance of an Intact Growth Hormone/Insulin-Like Growth Factor 1 Axis for Normal Post-Infarction Healing: Studies in Dwarf Rats Endocrinology, January 1, 2001; 142(1): 332 - 338. [Abstract] [Full Text] [PDF]

				L. Gianotti, A. I. Pincelli, M. Scacchi, M. Rolla, D. Bellitti, E. Arvat, F. Lanfranco, A. Torsello, E. Ghigo, F. Cavagnini, et al. Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Spontaneous and Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Anorexia Nervosa J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2805 - 2809. [Abstract] [Full Text]

				Y.-N. Sun, H. J. Lee, R. R. Almon, and W. J. Jusko A Pharmacokinetic/Pharmacodynamic Model for Recombinant Human Growth Hormone Effects on Induction of Insulin-Like Growth Factor I in Monkeys J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1523 - 1532. [Abstract] [Full Text]

				D. Grimm, D. Cameron, D. P. Griese, G. A.J. Riegger, and E. P. Kromer Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction Cardiovasc Res, November 1, 1998; 40(2): 297 - 306. [Abstract] [Full Text] [PDF]

				I. M. Chapman, M. L. Hartman, K. S. Pieper, E. H. Skiles, S. S. Pezzoli, R. L. Hintz, and M. O. Thorner Recovery of Growth Hormone Release from Suppression by Exogenous Insulin-Like Growth Factor I (IGF-I): Evidence for a Suppressive Action of Free Rather Than Bound IGF-I J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2836 - 2842. [Abstract] [Full Text]

				M. I. Lewis, A. T. Feinberg, and M. Fournier IGF-I and/or growth hormone preserve diaphragm fiber size with moderate malnutrition J Appl Physiol, July 1, 1998; 85(1): 189 - 197. [Abstract] [Full Text] [PDF]

				J. L. Thompson, G. E. Butterfield, U. K. Gylfadottir, J. Yesavage, R. Marcus, R. L. Hintz, A. Pearman, and A. R. Hoffman Effects of Human Growth Hormone, Insulin-Like Growth Factor I, and Diet and Exercise on Body Composition of Obese Postmenopausal Women J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1477 - 1484. [Abstract] [Full Text]

				V. Quarmby, C. Quan, V. Ling, P. Compton, and E. Canova-Davis How Much Insulin-Like Growth Factor I (IGF-I) Circulates? Impact of Standardization on IGF-I Assay Accuracy J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1211 - 1216. [Abstract] [Full Text]

				A. Cittadini, H. Stromer, D. E. Vatner, J. D. Grossman, S. E. Katz, R. Clark, J. P. Morgan, and P. S. Douglas Consequences of Growth Hormone Deficiency on Cardiac Structure, Function, and {beta}-Adrenergic Pathway: Studies in Mutant Dwarf Rats Endocrinology, December 1, 1997; 138(12): 5161 - 5169. [Abstract] [Full Text] [PDF]

				A. Juul, K. Holm, K. W. Kastrup, S. A. Pedersen, K. F. Michaelsen, T. Scheike, S. Rasmussen, J. Muller, and N. E. Skakkebak Free Insulin-Like Growth Factor I Serum Levels in 1430 Healthy Children and Adults, and Its Diagnostic Value in Patients Suspected of Growth Hormone Deficiency J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2497 - 2502. [Abstract] [Full Text] [PDF]

				M. I. Lewis, T. J. Lorusso, and M. Fournier Anabolic influences of insulin-like growth factor I and/or growth hormone on the diaphragm of young rats J Appl Physiol, June 1, 1997; 82(6): 1972 - 1978. [Abstract] [Full Text] [PDF]

				H. J. Lee, G. Riley, O. Johnson, J. L. Cleland, N. Kim, M. Charnis, L. Bailey, E. Duenas, A. Shahzamani, M. Marian, et al. J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1431 - 1439. [Abstract]

				M. I. Lewis, T. J. Lorusso, and M. Fournier Effect of insulin-like growth factor I and/or growth hormone on diaphragm of malnourished adolescent rats J Appl Physiol, April 1, 1997; 82(4): 1064 - 1070. [Abstract] [Full Text] [PDF]

				D. A. Sass, C. P. Jerome, A. R. Bowman, A. Bennett-Cain, T. A. Ginn, D. LeRoith, and S. Epstein Short-Term Effects of Growth Hormone and Insulin-Like Growth Factor I on Cancellous Bone in Rhesus Macaque Monkeys J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1202 - 1209. [Abstract] [Full Text] [PDF]

				R. Clark, K. Olson, G. Fuh, M. Marian, D. Mortensen, G. Teshima, S. Chang, H. Chu, V. Mukku, E. Canova-Davis, et al. Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol J. Biol. Chem., September 6, 1996; 271(36): 21969 - 21977. [Abstract] [Full Text] [PDF]

				H. Stromer, A. Cittadini, P. S. Douglas, and J. P. Morgan Exogenously Administered Growth Hormone and Insulin-like Growth Factor-I Alter Intracellular Ca2+ Handling and Enhance Cardiac Performance: In Vitro Evaluation in the Isolated Isovolumic Buffer-Perfused Rat Heart Circ. Res., August 1, 1996; 79(2): 227 - 236. [Abstract] [Full Text]

				R. L. Duerr, M. D. McKirnan, R. D. Gim, R. G. Clark, K. R. Chien, and J. Ross Jr Cardiovascular Effects of Insulin-Like Growth Factor-1 and Growth Hormone in Chronic Left Ventricular Failure in the Rat Circulation, June 15, 1996; 93(12): 2188 - 2196. [Abstract] [Full Text]

				A. Cittadini, H. Stromer, S. E. Katz, R. Clark, A. C. Moses, J. P. Morgan, and P. S. Douglas Differential Cardiac Effects of Growth Hormone and Insulin-like Growth Factor1 in the Rat : A Combined In Vivo and In Vitro Evaluation Circulation, February 15, 1996; 93(4): 800 - 809. [Abstract] [Full Text]